Evidence map›Paper›PMID 39850599›Full record

ArticleJournal of traditional and complementary medicine2024

Effect of

Chun-Chung Chen, Hung-Lin Lin, Jeng-Hung Guo, XianXiu Chen, Der-Yang Cho, Wen-Ling Liao, Ching-Liang Hsieh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional and complementary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chun-Chung ChenGraduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
Hung-Lin LinDepartment of Neurosurgery, China Medical University Hospital, Taichung, Taiwan.
Jeng-Hung GuoDepartment of Neurosurgery, China Medical University Hospital, Taichung, Taiwan.
XianXiu ChenDepartment of Neurosurgery, China Medical University Hospital, Taichung, Taiwan.
Der-Yang ChoDepartment of Neurosurgery, China Medical University Hospital, Taichung, Taiwan.
Wen-Ling LiaoGraduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
Ching-Liang HsiehGraduate Institute of Acupuncture Science, China Medical University, Taichung, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Experimental procedure: Eighty-eight patients experiencing acute aSAH were randomly allocated to either the treatment group (TG) comprising 44 patients, who received 3 g of AM orally thrice daily for 14 days, or the control group (CG) with 44 patients, who received 3 g of a placebo. Results: Eighty-three patients (41 in CG and 42 in TG) completed the trial. Stratified analyses revealed serum interleukin-6 (IL-6) median ≥7.28 pg/mL at baseline. The percentage of good GOS scores (GOS 4 or 5) at two weeks (W2) and four weeks (W4) was significantly higher in TG than in CG (W2: 35.3 % vs. 7.7 %, Conclusion: Administering AM for 14 days has shown potential in enhancing neurological function four weeks post-aSAH onset, especially in patients with a serum IL-6 level median ≥7.28 pg/mL. Therefore, further research is warranted to explore the anti-inflammatory role of AM. However, this study's limitations include a small sample size and the single-center design, signifying its status as a preliminary investigation.

Indexed as

Aneurysmal subarachnoid hemorrhageAstragalus membranaceusGlasgow outcome scaleInterleukin-6Modified rankin scale

Identifiers

PMID39850599
PMCPMC11752111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.